Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world association between adverse events and plasma concentrations of ibrutinib and idelalisib in hematological malignancies
2015-005572-17Phase 4Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ibrutinib and idelalisib in hematopoietic malignancies, lymphoma and cancer (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Clinically significant adverse events within first year. Started Apr 2016; status: terminated.
02
Drugs
ibrutinibidelalisib
03
Conditions
hematopoietic malignancieslymphomacancer
Beyond the preview
Go deeper on 2015-005572-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005572-17.